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L E T T E R  T O  T H E  E D I T O R
RNA-seq–based profiling of extracellular vesicles in plasma 
reveals a potential role of miR-122-5p in asthma
To the Editor,
Asthma is a heterogeneous disease encompassing several distinct 
sub-phenotypes with different etiologies and treatment responses,1 
but we are lacking markers to differentiate patient subgroups.
MicroRNAs (miRNAs) can regulate gene expression post-tran-
scriptionally. Due to their high stability in body fluids, their easy 
detection, and their functional relevance in asthma, we and others 
have proposed extracellular miRNAs in noninvasive clinical samples 
as biomarkers for asthma.2,3 Yet, extracellular miRNA profiles can 
be confounded by unspecific release of miRNAs from dying cells. 
Transfer of miRNAs by extracellular vesicles (EVs) is, however, sup-
posedly a selective communication mechanism,4 and EV-miRNA lev-
els have been shown to be altered in bronchoalveolar lavage (BAL) 
fluid of patients with asthma.5 In this pilot study, we profiled the EV-
miRNA signature in plasma of patients with mild-to-moderate (AM) 
or severe eosinophilic asthma (AS) (as defined by ERS/ATS guide-
lines6) and healthy control (HC) subjects (Tables S1 and S2).
Therefore, we isolated small EVs (EVs) (<200 nm) by size exclu-
sion chromatography (SEC) (qEV, Izon Bioscience) from 1 mL plasma 
of 45 adult subjects with AM (n = 15) or AS (n = 14), and HC (n = 16) 
(Table S1). All study participants were enrolled in the all age asthma 
(ALLIANCE) cohort, a multi-center longitudinal asthma patient co-
hort of the German Center for Lung Research (DZL).7
SEC-isolated particles were confirmed to be <200 nm by 
nanoparticle tracking analysis (NTA) (ZetaView PMX 110, Particle 
Metrix) and were equal in concentration and size distribution 
across groups (Figure 1A). The median particle concentration iso-
lated from 1 mL of plasma was 8.6 × 109 particles/mL (interquartile 
range [IQR]: 4.5 × 109-1.4 × 1010) for HC, 1.2 × 1010 particles/mL 
(IQR: 6.6 × 109-2.8 × 1010) for AM, and 1.0 × 1010 particles/mL (IQR: 
3.9 × 109-3.6 × 1010) for AS. Furthermore, SEC fractions 7-9 used for 
sequencing were without protein contamination (Figure 1B) and ex-
pressed different amounts of typical small EV markers CD63, CD81, 
and/or CD9 (Figure S1).
EV-RNA was isolated (miRNeasy Micro Kit; Qiagen) and subjected 
to RNA sequencing (RNA-seq) (HiSeq 2500, Illumina) of small RNAs 
(below 35 nt) according to Ref.8 While all samples achieved high 
Phred scores (>30) indicating excellent sequencing quality (Figure 
S2A), 46.42% of reads were short or unmapped (39.11%) (Figure 1C). 
From all mapped reads, 17.15% were classified as miRNAs, while 
81.08% were ribosomal RNAs. In total, we detected 139 distinct EV 
miRNAs with ≥10 reads (AM: 115; AS: 114; HC: 128) (Figure S2B, 
Tables S3-S5), and 35 of which had read counts ≥ 50. Unsupervised 
clustering and principal component analysis did not separate the dif-
ferent groups (Figure S2C, D), indicating that there is no difference 
between asthma patients and healthy controls based on total EV-
miRNA expression. However, miR-122-5p was significantly increased 
in all patients with asthma (log2 fold change (log2FC) = 1.74, false 
discovery rate (FDR) = 0.03) and in AS (log2FC = 1.77, FDR = 0.02) 
compared with healthy controls, while miR-3168 was decreased 
(log2FC = −1.28; FDR = 0.05) (Figure 1D). In AS, we found similar 
trend for miR-191-5p (log2FC = 0.39, FDR = 0.12) (Figure 1E).
In a bivariate analysis, miR-191-5p normalized read counts cor-
related negatively with FEV1%pred (Spearman's R = −.38; P = .013) 
and lymphocyte percentage in blood (R = −.5; P = .0006) (Figure 1F). 
We found a positive correlation with blood neutrophil (R = .48; 
P = .0012) counts and a similar trend for blood eosinophil counts 
(R = .29; P = .058). miR-3168 read counts correlated significantly 
with blood eosinophils (R = −.28, P = .012), neutrophils (R = −.3, 
P = .05), and lymphocytes (R = .38, P = .012). Read counts of miR-
122-5p positively correlated with both eosinophil (R = .32; P = .034) 
and neutrophil (R = .39; P = .0094) counts in blood, and trendwise 
with blood lymphocytes (R = −.28; P = .065) (Figure 1F). We do ac-
knowledge that some correlation coefficients are quite low (R < .3) 
which could be due to the small sample size and needs to be con-
firmed in larger future studies.
Next, we isolated EVs from additional plasma samples of the 
same subjects and 10 new subjects per group (Figure 2A), and found 
a strong trend for an increase of miR-122-5p (FC = 1.84; P = .07) 
in severe asthma, and in all asthma subjects (FC = 1.96; P = .09) 
(Figure 2A) by RT-qPCR, confirming the sequencing results. miR-
191-5p did not differ significantly among the groups, and miR-3168 
was not detectable by RT-qPCR. Of note, in a pilot approach both 
miRNAs could also be detected in EVs isolated from sputum super-
natant samples of four healthy control and ten asthma subjects, 
and we have a first hint that they are increased in asthma compared 
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F I G U R E  1   small RNA sequencing from plasma EVs. A, EV concentration (left panel), size distribution, and median size (right panels) 
in plasma EV isolations from healthy controls (HC, n = 16), mild-to-moderate (AM, n = 15), or severe asthma (AS, n = 14) assessed by 
nanoparticle tracking analysis (lines represent median). B, Protein content of qEV fractions in mg/mL, assessed by microBCA (n = 45 per 
fraction, mean ± SD). C, Sequencing distribution of small RNA classes in %, with relative distribution within mapped reads (right) (D and E) 
10 top-regulated miRNAs (sorted by log2 fold change) in asthma patients vs HC (D) and AM vs HC (left) and AS vs HC (right) (E); FDR = false 
discovery rate. F, Spearman's correlations of miR-122-5p (upper panels), miR-3168 (middle panels), and miR-191-5p (lower panels) read counts 
with clinical characteristics of all included subjects (n = 45), and each graph depicts correlation co-efficient R and P-value
F I G U R E  2   EV-miRNA from plasma correlates with clinical characteristics of asthma. A and B, RT-qPCR for miR-122-5p and miR-191-5p 
normalized to miR-21 levels (reference) in (A) plasma EVs from healthy controls (HC, n = 26), all asthma (n = 51), mild-to-moderate (AM, 
n = 25) or severe asthma (AS, n = 26), or (B) sputum supernatant EVs from healthy controls (HC, n = 4) and patients with asthma (n = 10). 
All Mann–Whitney U to HC or AM. *P ≤ .05, **P ≤ .01, ***P ≤ .001. Graphs depict fold changes to healthy controls with lines indicating the 
median. (C) Ingenuity pathway analysis showing association of miR-122-5p and miR-191-5p with quantity of leukocytes, function of antigen-
presenting cells, activation of antigen-presenting cells, function of Th2 cells, quantity of regulatory T lymphocytes, and differentiation of Th2 cells
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with healthy controls (miR-122-5p: FC = 2.90; P = .014; miR-191-5p: 
FC = 2.69, P = .014) (Figure 2B).
Ingenuity Pathway Analysis (IPA) of predicted targets of miR-
122-5p and miR-191-5p revealed a concise network, containing the 
biological functions quantity of leukocytes, function of antigen-pre-
senting cells, activation of antigen-presenting cells, function of Th2 
cells, quantity of regulatory T lymphocytes, and differentiation of Th2 
cells (Figure 2C). This is a first hint that miR-122-5p (and potentially 
miR-191-5p) could influence immune cell function upon uptake. This 
could systemically perpetuate the asthmatic phenotype and should 
be confirmed in larger studies, where also the specificity for asthma 
vs a general immune reaction should be assessed.
The relatively low number of significantly altered miRNAs here 
might be due to the isolation of highly pure EVs by SEC. This is in 
line with previous reports,8 but SEC isolation is superior to other 
methods in separating EVs from contaminating proteins.9 Further, 
we have here focused on eosinophilic asthma of different severities, 
hampering comparisons of different asthma sub-phenotypes. This 
will require considerably larger patient numbers and was thus be-
yond the scope of this study.
In summary, in relatively well-controlled asthma the total miRNA 
expression in plasma EVs is not different to controls. miR-122-5p is 
increased in plasma and sputum supernatant EVs derived from pa-
tients with (severe) asthma, and this miRNA correlated with immune 
cell types in the blood. Combined with the IPA-predicted role in lym-
phocyte differentiation and function, it is intriguing to speculate that 
this miRNA can sub-differentiate different forms of asthma, such as 
neutrophilic from eosinophilic asthma. This should be investigated 
in larger asthma cohort studies with a broad spectrum of clinically 
well-defined phenotypes and different treatment regimen also in-
cluding steroid-naïve patients.
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